Exact Mass: 337.2014884
Exact Mass Matches: 337.2014884
Found 373 metabolites which its exact mass value is equals to given mass value 337.2014884,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Lobeline
(-)-lobeline is an optically active piperidine alkaloid having a 2-oxo-2-phenylethyl substituent at the 2-position and a 2-hydroxy-2-phenylethyl group at the 6-position. It has a role as a nicotinic acetylcholine receptor agonist. It is a piperidine alkaloid, a tertiary amine and an aromatic ketone. Lobeline is a natural product found in Lobelia sessilifolia, Lobelia inflata, and other organisms with data available. An alkaloid that has actions similar to NICOTINE on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D005731 - Ganglionic Stimulants C78272 - Agent Affecting Nervous System > C47796 - Cholinergic Agonist > C73579 - Nicotinic Agonist D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018679 - Cholinergic Agonists D019141 - Respiratory System Agents relative retention time with respect to 9-anthracene Carboxylic Acid is 0.733 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.728
Danazol
Danazol is a synthetic steroid with anti-oestrogenic and anti progestogenic activity, and weak androgenic properties. Danazol suppresses oestrogen and progesterone receptors in the endometrium, leading to endometrial atrophy (thinning of the lining of the uterus) and reduced menstrual loss and to amenorrhoea in some women. Danazol significantly lowers the duration of menses when compared with NSAIDs and a progesterone releasing IUD; however, caused more adverse events than NSAIDs and progestogens. The use of Danazol may be limited by its side effect profile, its acceptability to women and the need for continuing treatment. Because danazol is structurally related to the anabolic steroid stanozolol, its use should be questioned. Derivatization methods and GC/MS data are used to implement danazol detection in routine screening and confirmation procedures in doping analysis. Danazol main metabolite ethisterone is excreted relatively fast in urine. (PMID: 17636649, 1640693, 16288903) [HMDB] Danazol is a synthetic steroid with anti-oestrogenic and anti progestogenic activity, and weak androgenic properties. Danazol suppresses oestrogen and progesterone receptors in the endometrium, leading to endometrial atrophy (thinning of the lining of the uterus) and reduced menstrual loss and to amenorrhoea in some women. Danazol significantly lowers the duration of menses when compared with NSAIDs and a progesterone releasing IUD; however, caused more adverse events than NSAIDs and progestogens. The use of Danazol may be limited by its side effect profile, its acceptability to women and the need for continuing treatment. Because danazol is structurally related to the anabolic steroid stanozolol, its use should be questioned. Derivatization methods and GC/MS data are used to implement danazol detection in routine screening and confirmation procedures in doping analysis. Danazol main metabolite ethisterone is excreted relatively fast in urine. (PMID: 17636649, 1640693, 16288903). CONFIDENCE standard compound; INTERNAL_ID 253; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9896; ORIGINAL_PRECURSOR_SCAN_NO 9894 CONFIDENCE standard compound; INTERNAL_ID 253; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9859; ORIGINAL_PRECURSOR_SCAN_NO 9858 CONFIDENCE standard compound; INTERNAL_ID 253; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9824; ORIGINAL_PRECURSOR_SCAN_NO 9822 CONFIDENCE standard compound; INTERNAL_ID 253; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9882; ORIGINAL_PRECURSOR_SCAN_NO 9880 CONFIDENCE standard compound; INTERNAL_ID 253; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9866; ORIGINAL_PRECURSOR_SCAN_NO 9865 CONFIDENCE standard compound; INTERNAL_ID 253; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9843; ORIGINAL_PRECURSOR_SCAN_NO 9841 G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03X - Other sex hormones and modulators of the genital system > G03XA - Antigonadotropins and similar agents D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2092 - Gonadotropin Releasing Hormone Antagonist C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid
Olopatadine
C21H23NO3 (337.16778480000005)
Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AC - Antiallergic agents, excl. corticosteroids D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D018926 - Anti-Allergic Agents
Bitertanol
D016573 - Agrochemicals D010575 - Pesticides
Kyotorphin
C15H23N5O4 (337.17499580000003)
Kyotorphin (L-tyrosyl-L-arginine) is a neuroactive dipeptide which plays a role in pain regulation in the brain. It was first isolated from bovine brain by Japanese scientists in 1979. Kyotorphin was named for the site of its discovery, Kyoto, Japan and because of its morphine- (or endorphin-) like analgesic activity. Kyotorphin has an analgesic effect, but it does not interact with the opioid receptors. Instead, it acts by releasing an Met-enkephalin and stabilizing it from degradation. It may also possess properties of neuromediator/neuromodulator. It has been shown that kyotorphin is present in the human cerebrospinal fluid and that it is lower in patients with persistent pain. [HMDB] Kyotorphin (L-tyrosyl-L-arginine) is a neuroactive dipeptide which plays a role in pain regulation in the brain. It was first isolated from bovine brain by Japanese scientists in 1979. Kyotorphin was named for the site of its discovery, Kyoto, Japan and because of its morphine- (or endorphin-) like analgesic activity. Kyotorphin has an analgesic effect, but it does not interact with the opioid receptors. Instead, it acts by releasing an Met-enkephalin and stabilizing it from degradation. It may also possess properties of neuromediator/neuromodulator. It has been shown that kyotorphin is present in the human cerebrospinal fluid and that it is lower in patients with persistent pain. D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides D018377 - Neurotransmitter Agents > D004723 - Endorphins Kyotorphin is an endogenou neuroactive dipeptide with analgesic properties. Kyotorphin possesses anti-inflammatory and antimicrobial activity. Kyotorphin levels in cerebro-spinal fluid correlate negatively with the progression of neurodegeneration in Alzheimer's Disease patients[1].
Nemorensine
3,6-Ditigloyloxytropan-7-ol
3,6-Ditigloyloxytropan-7-ol is found in fruits. 3,6-Ditigloyloxytropan-7-ol is an alkaloid present in Cyphomandra betacea (tree tomato
Arginyltyrosine
C15H23N5O4 (337.17499580000003)
Arginyltyrosine is a dipeptide composed of arginine and tyrosine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Tyrosyl-Arginine
C15H23N5O4 (337.17499580000003)
Tyrosyl-Arginine is a dipeptide composed of tyrosine and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Dodeca-3,6,9-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-3,6,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,6,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,6,9-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,6,9-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-2,5,8-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-2,5,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-2,5,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-2,5,8-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-2,5,8-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine
C19H31NO4 (337.22529660000004)
(4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6E,10E)-dodeca-4,6,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,6,8-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-4,6,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,6,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,6,8-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,6,8-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,7,10-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-4,7,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,7,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,7,10-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,7,10-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-2,4,6-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-2,4,6-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-2,4,6-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-2,4,6-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-3,5,7-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-3,5,7-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,5,7-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,5,7-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-6,8,10-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-6,8,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-6,8,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-6,8,10-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-6,8,10-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-5,7,9-trienoylcarnitine
C19H31NO4 (337.22529660000004)
Dodeca-5,7,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,7,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,7,9-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,7,9-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Lauroyl Histidine
C18H31N3O3 (337.23652960000004)
N-lauroyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
suloctidil
C20H35NOS (337.24392200000005)
Posiphen
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D004791 - Enzyme Inhibitors
3-Quinuclidinyl benzilate
C21H23NO3 (337.16778480000005)
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
Furylacryloylalanyllysine
C16H23N3O5 (337.16376280000003)
3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide
C21H23NO3 (337.16778480000005)
Amineptine
N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants > N06AA - Non-selective monoamine reuptake inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
Danatrol
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists
2-[11-[3-(Dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
C21H23NO3 (337.16778480000005)
H-D-Tyr-val-gly-OH
C16H23N3O5 (337.16376280000003)
Inflatine
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D005731 - Ganglionic Stimulants D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018679 - Cholinergic Agonists D019141 - Respiratory System Agents
N-(p-Amylcinnamoyl)anthranilic acid
C21H23NO3 (337.16778480000005)
Oclacitinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor
Pafenolol
C18H31N3O3 (337.23652960000004)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
Pargeverine
C21H23NO3 (337.16778480000005)
Propanidid
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics N - Nervous system > N01 - Anesthetics > N01A - Anesthetics, general C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
1-Azabicyclo[2.2.2]octan-2-yl 2-hydroxy-2,2-diphenylacetate
C21H23NO3 (337.16778480000005)
3alpha-(3,4,5-Trimethoxybenzoyloxy)nortropan-6beta-ol
1-methyl-2-(4z,7z)-4,7-tridecadienyl-4(1h)-quinolinone
Amineptine
A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne. N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants > N06AA - Non-selective monoamine reuptake inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
3alpha-(E)-4-hydroxysenecioyloxy-6beta-senecioyloxytropane
N1=C(C)C(CCCCCC)=CC1=CC1=C(OC)C=C(C=2NC=CC=2)N1
C21H27N3O (337.21540120000003)
(Xi)-beta-D-Glucopyranosyloxy-(4-isopropyl-phenyl)-acetonitril|(Xi)-beta-D-glucopyranosyloxy-(4-isopropyl-phenyl)-acetonitrile
1-O-beta-D-glucopyranosyl-5-deoxyadenophorine|1-O-beta-D-glucopyranosyladenophorine
4-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]-5-oxo-5-phenylmethoxypentanoic acid
(16aR)-8-Formyl-13t-((S)-1-hydroxy-propyl)-(16ar)-1,4,5,6,7,8,9,10,11,13,16,16a-dodecahydro-3H-pyrido[2,1-d][1,5,9]triazacyclotridecin-2-on|(16aR)-8-formyl-13t-((S)-1-hydroxy-propyl)-(16ar)-1,4,5,6,7,8,9,10,11,13,16,16a-dodecahydro-3H-pyrido[2,1-d][1,5,9]triazacyclotridecin-2-one|8-formyl-4-(1-hydroxy-propyl)-1,4,6,7,8,9,10,11,12,13,15,15a-dodecahydro-5H-4a,8,13-triaza-benzocyclotridecen-14-one|Palustridin|Palustridine
C18H31N3O3 (337.23652960000004)
9-(4-aminophenyl)-3,7-dihydroxy-2,4,6-trimethyl-9-oxo-nonoic acid
5-hydroxy-4,5-dimethyl-3-(propan-2-yl)-4,5,8,10,12,13,13a,13b-octahydro-2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3h)-dione
3alpha-(E)-4-hydroxysenecioyloxy-6beta-angeloyloxytropane
RCS-4 N-(4-hydroxypentyl) metabolite
C21H23NO3 (337.16778480000005)
suloctidil
C20H35NOS (337.24392200000005)
C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
RCS-4 N-(5-hydroxypentyl) metabolite
C21H23NO3 (337.16778480000005)
1-Methyl-2-(4Z,7Z)-4,7-tridecadienyl-4(1H)-quinolone
Olopatadine
C21H23NO3 (337.16778480000005)
R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AC - Antiallergic agents, excl. corticosteroids D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D018926 - Anti-Allergic Agents CONFIDENCE standard compound; INTERNAL_ID 2210 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3323
Danazol
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03X - Other sex hormones and modulators of the genital system > G03XA - Antigonadotropins and similar agents D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2092 - Gonadotropin Releasing Hormone Antagonist C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid
Fenpiverinium
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
9-(4-aminophenyl)-3,7-dihydroxy-2,4,6-trimethyl-9-oxo-nonoic acid (candicidin related)
Lobron
Origin: Plant; Formula(Parent): C22H27NO2; Bottle Name:Lobeline hemisulfate; PRIME Parent Name:Lobeline; PRIME in-house No.:V0345; SubCategory_DNP: Alkaloids derived from lysine, Lobelia alkaloids
Methylmibefradil Metabolite (Acetic acid, methoxy-, 6-fluoro-1,2,3,4-tetrahydro-2-[2-(methylamino)et
C19H28FNO3 (337.20531100000005)
Arg-Tyr
C15H23N5O4 (337.17499580000003)
A dipeptide formed from L-arginine and L-tyrosine residues.
3,6-Ditigloyloxytropan-7-ol
1-[(TERT-BUTYL)OXYCARBONYL]-3-(4-FLUOROBENZYL)PIPERIDINE-3-CARBOXYLIC ACID
N-ethyl-N-(6-methoxyquinolin-8-yl)-N-propan-2-yl-propane-1,3-diamine
C18H28ClN3O (337.19207880000005)
tert-butyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-ioxaborolan-2-yl)phenylcarbamate
C17H25BFNO4 (337.18605720000005)
1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(3-phenylpyrrolidin-1-yl)propan-1-one
C21H23NO3 (337.16778480000005)
(4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylene-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
C21H23NO3 (337.16778480000005)
4-[(4-METHOXYBENZYLIDENE)AMINO]CINNAMIC ACID N-BUTYL ESTER
C21H23NO3 (337.16778480000005)
tert-butyl 4-(3-methoxy-4-nitrophenyl)piperazine-1-carboxylate
C16H23N3O5 (337.16376280000003)
N-(2,5,8,11,14-pentaoxabicyclo[13.4.0]nonadeca-1(15),16,18-trien-17-yl)prop-2-enamide
N-(4-methoxyphenyl)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanimine
H-D-Tyr-Val-Gly-OH
C16H23N3O5 (337.16376280000003)
(4-METHOXY-BENZYLIDENE)-[3-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PHENYL]-AMINE
N-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
Pargeverine
C21H23NO3 (337.16778480000005)
D000890 - Anti-Infective Agents > D000892 - Anti-Infective Agents, Urinary > D008333 - Mandelic Acids C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent
1-((4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)SULFONYL)PYRROLIDINE
C16H24BNO4S (337.15190140000004)
1-BENZYL-3-(3-DIETHYLAMINOPROPYLOXY)-1H-INDAZOLE
C21H27N3O (337.21540120000003)
1-O-tert-butyl 4-O-methyl 2-(phenylmethoxycarbonylamino)butanedioate
Benzhexol hydrochloride
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
Oxiperomide
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
1-Methyllysergic acid diethylamide
C21H27N3O (337.21540120000003)
piperidinomethyl-3-phenylboronic acid pinacol ester hydrochloride
Phenserine
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D004791 - Enzyme Inhibitors
ethyl 2-piperazine-4-cyclopentylethyl thiazole-5-carboxylate
8-Boc-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-8-aza-bicyclo[3.2.1]octane
C18H32BNO4 (337.24242620000007)
tert-Butyl 4-(5-methoxy-2-nitrophenyl)piperazine-1-carboxylate
C16H23N3O5 (337.16376280000003)
methyl 2-[[3-(4-tert-butylphenyl)-2-methylpropylidene]amino]benzoate
4-[[[2-(Diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid tert-butyl ester
C18H31N3O3 (337.23652960000004)
AMG 9810
C21H23NO3 (337.16778480000005)
N-benzyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
Posiphen
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors C78272 - Agent Affecting Nervous System D004791 - Enzyme Inhibitors
6-[(Z)-2-(2,5-dimethoxyphenyl)ethenyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
C18H19N5O2 (337.15386739999997)
N-(p-Amylcinnamoyl)anthranilic acid
C21H23NO3 (337.16778480000005)
N-(p-amylcinnamoyl) Anthranilic Acid (ACA) is a broad spectrum Phospholipase A2 (PLA2) inhibitor and TRP channel blocker[1][2]. N-(p-amylcinnamoyl) Anthranilic Acid (ACA) is also an effective reversible inhibitor of calcium-activated chloride channels, has potential to treat arrhythmia[3].
N4,N6-dicyclopentyl-2-(methylthio)-5-nitropyrimidine-4,6-diamine
GS39783 is a positive allosteric modulator (PAM) of GABABR. Positive modulation of the GABABR can be used for the research of Nicotine addiction[1].
PF-670462 free base
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
Decimemide
C19H31NO4 (337.22529660000004)
C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
1-(2,4-Dimethylphenyl)-4-piperidin-1-ylsulfonylpiperazine
4-[2-(Dimethylamino)ethylamino]-3-benzo[h]quinolinecarboxylic acid ethyl ester
2-Piperidinone, 1-[1-oxo-3-[4-(phenylmethoxy)phenyl]propyl]-
C21H23NO3 (337.16778480000005)
Cerebro
C20H35NOS (337.24392200000005)
C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
(2S)-N-[(3Z)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxoimidazolidin-1-YL)phenyl]propanamide
C18H19N5O2 (337.15386739999997)
Sombrevin
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics N - Nervous system > N01 - Anesthetics > N01A - Anesthetics, general C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
Oclacitinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor
Tabersoninium(1+)
C21H25N2O2+ (337.19159299999995)
Conjugate acid of tabersonine arising from protonation of the tertiary amino group; major species at pH 7.3.
Plaquenil
C18H28ClN3O+2 (337.19207880000005)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D018501 - Antirheumatic Agents D004791 - Enzyme Inhibitors
monacolin J carboxylate
A hydroxy monocarboxylic acid anion that is the conjugate base of monacolin J acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Catharanthine(1+)
C21H25N2O2+ (337.19159299999995)
An ammonium ion resulting from thr protonation of the tertiary amino group of catharanthine. D000970 - Antineoplastic Agents > D014748 - Vinca Alkaloids
Dehydrosecodine(1+)
C21H25N2O2+ (337.19159299999995)
A tertiary ammonium ion result from the protonation of the tertiary amino group of dehydrosecodine (the enamine form). An intermediate in the biosynthesis of aspidospermaand iboga alkaloids.
(3Z,5S)-3-(1-oxidoethylidene)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}pyrrolidine-2,4-dione(1-)
C20H21N2O3- (337.15520960000003)
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(2,5-diaminopentyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[3-(methylamino)propylamino]methyl]oxolane-3,4-diol
(2S,3S)-3-methyl-2-[[2-[(1R,2S)-3-oxo-2-[(Z)-5-oxopent-2-enyl]cyclopentyl]acetyl]amino]pentanoic acid
(4E,6E,10E)-Dodeca-4,6,10-trienoylcarnitine
C19H31NO4 (337.22529660000004)
tricyclamol chloride
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent
Danazol, United States PharmacopeiaReference Standard
5-amino-1-[(3-methoxyphenyl)methyl]-N-(4-methylphenyl)-4-triazolecarboxamide
C18H19N5O2 (337.15386739999997)
N-(1,4-Dihydroxy-4-methylpentan-2-YL)-3-hydroxy-5-oxo-6-phenylhexanamide
3,4-dimethyl-N-[[4-(4-methylpiperazin-1-yl)phenyl]methyl]benzamide
C21H27N3O (337.21540120000003)
4-{[4-(4-Methyl-benzyl)-piperazin-1-ylimino]-methyl}-benzoic acid
(5Z,11Z,14Z)-8,9-Dihydroxyicosa-5,11,14-trienoate
C20H33O4- (337.23787180000005)
1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)-3-[3-(dimethylamino)propyl]-1-ethylthiourea
(5Z,8Z,11Z)-14,15-dihydroxyicosatrienoate
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5Z,8Z,14Z)-11,12-dihydroxyicosatrienoate
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12-HPE(8,10,14)TrE(1-)
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of 12-HPE(8,10,14)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12(S)-HPE(5,8,10)TrE(1-)
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of 12(S)-HPE(5,8,10)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12(S)-HPE(8,10,14)TrE(1-)
C20H33O4- (337.23787180000005)
A polyunsaturated fatty acid anion that is the conjugate base of 12(S)-HPE(8,10,14)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
1-(4-Chlorophenyl)-1-cyclohexyl-3-(4-morpholinyl)-1-propanol
C19H28ClNO2 (337.18084580000004)
(1Z)-1-[(5S)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}-2,4-dioxopyrrolidin-3-ylidene]ethanolate
C20H21N2O3- (337.15520960000003)
(8R,9E,11Z,14Z)-8-hydroperoxyicosatrienoate
C20H33O4- (337.23787180000005)
(8Z,11Z,14Z)-10-hydroperoxyicosatrienoate
C20H33O4- (337.23787180000005)
(8Z,12E,14Z)-11-hydroperoxyicosatrienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11R,12R,14Z)-11,12-dihydroxyicosa-5,8,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11Z,14S,15S)-14,15-dihydroxyicosa-5,8,11-trienoate
C20H33O4- (337.23787180000005)
(5Z,8R,9R,11Z,14Z)-8,9-dihydroxyicosa-5,11,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8S,9S,11Z,14Z)-8,9-dihydroxyicosa-5,11,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11S,12S,14Z)-11,12-dihydroxyicosa-5,8,14-trienoate
C20H33O4- (337.23787180000005)
(5Z,8Z,11Z,14R,15R)-14,15-dihydroxyicosa-5,8,11-trienoate
C20H33O4- (337.23787180000005)
(15S)-hydroperoxy-(8Z,11Z,13E)-eicosatrienoate
C20H33O4- (337.23787180000005)
4-[2-[[(4-Fluorophenyl)-oxomethyl]amino]ethylamino]-1-piperidinecarboxylic acid ethyl ester
N-[2-(diethylamino)ethyl]-2-(2-furanyl)-4-quinolinecarboxamide
4-[2-[[(3-Fluorophenyl)-oxomethyl]amino]ethylamino]-1-piperidinecarboxylic acid ethyl ester
[(8S,9S,10R)-6-methyl-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C21H27N3O (337.21540120000003)
[(8R,9R,10S)-6-methyl-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C21H27N3O (337.21540120000003)
Methyl (2E,3E,5E,7E)-13-amino-2-ethylidene-11,12-dihydroxy-4,10-dimethyl-13-oxotrideca-3,5,7-trienoate
(5S,12S)-dihydroxy-(6Z,8E,14Z)-icosatrienoate
C20H33O4- (337.23787180000005)
10,11-epoxy-12-hydroxy-(14Z,17Z)-eicosadienoate
C20H33O4- (337.23787180000005)
14,15-epoxy-12-hydroxy-(10E,17Z)-eicosadienoate
C20H33O4- (337.23787180000005)
1-Acetoxy-3-(N-acetyl-2-acetoxyethylamino)-5-methoxy-2,6-dimethylbenzene
N-Trimethylsilylphenylacetylglycine trimethylsilyl ester
(E)-3-(Benzylamino)-5-phenyl-4-pentenoic acid tert-butyl ester
methyl (1R,12S,14S,15Z)-15-ethylidene-17-methyl-3-aza-17-azoniapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4,6,8-tetraene-13-carboxylate
C21H25N2O2+ (337.19159299999995)
Kyotorphin
C15H23N5O4 (337.17499580000003)
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides D018377 - Neurotransmitter Agents > D004723 - Endorphins Kyotorphin is an endogenou neuroactive dipeptide with analgesic properties. Kyotorphin possesses anti-inflammatory and antimicrobial activity. Kyotorphin levels in cerebro-spinal fluid correlate negatively with the progression of neurodegeneration in Alzheimer's Disease patients[1].
Fenpiverinium
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
Danatrol
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists
(5Z,11Z,14Z)-8,9-dihydroxyicosatrienoate
A polyunsaturated fatty acid anion that is the conjugate base of (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(3Z,5S)-3-(1-oxidoethylidene)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}pyrrolidine-2,4-dione(1-)
C20H21N2O3 (337.15520960000003)
Conjugate base of (3Z,5S)-3-(1-hydroxyethylidene)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}pyrrolidine-2,4-dione arising from deprotonation of the enolic hydroxy group; major species at pH 7.3.
(5Z,8Z,11S,12S,14Z)-11,12-dihydroxyicosatrienoate
A (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8Z,11S,12S,14Z)-11,12-dihydroxyicosatrienoic acid; major species at pH 7.3.
(5Z,8Z,11Z,14R,15R)-14,15-dihydroxyicosatrienoate
A (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8Z,11Z,14R,15R)-14,15-dihydroxyicosatrienoic acid; major species at pH 7.3.
10,11-dihydroleukotriene B4(1-)
An icosanoid anion that is the conjugate base of 10,11-dihydroleukotriene B4, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5Z,8S,9S,11Z,14Z)-8,9-dihydroxyicosatrienoate
A (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8S,9S,11Z,14Z)-8,9-dihydroxyicosatrienoic acid; major species at pH 7.3.
(5Z,8Z,11R,12R,14Z)-11,12-dihydroxyicosatrienoate
A (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8Z,11R,12R,14Z)-11,12-dihydroxyicosatrienoic acid; major species at pH 7.3.
(5Z,8Z,11Z,14S,15S)-14,15-dihydroxyicosatrienoate
A (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8Z,11Z,14S,15S)-14,15-dihydroxyicosatrienoic acid; major species at pH 7.3.
(5Z,8R,9R,11Z,14Z)-8,9-dihydroxyicosatrienoate
A (5Z,11Z,14Z)-8,9-dihydroxyicosatrienoate obtained by deprotonation of the carboxy group of (5Z,8R,9R,11Z,14Z)-8,9-dihydroxyicosatrienoic acid; major species at pH 7.3.
(-)-Lobeline
An optically active piperidine alkaloid having a 2-oxo-2-phenylethyl substituent at the 2-position and a 2-hydroxy-2-phenylethyl group at the 6-position.
angryline(1+)
C21H25N2O2 (337.19159299999995)
A methyl ester resulting from the formal condensation of the carboxy group of (5S,12bR,12cS)-7-carboxy-1-ethyl-3,6,8,12c-tetrahydro-4H-5,12b-ethanoindolo[3,2-a]quinolizin-5-ium with methanol.
AcCa(12:3)
C19H31NO4 (337.22529660000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
S1RA
S1RA (E-52862) is a highly selective σ1 receptor (σ1R) antagonist with Kis of 17 nM and 23.5 nM for human σ1R and guinea pig σ1R, respectively. S1RA has Moderate antagonistic activity for human 5-HT2B receptor (Ki= 328 nM). S1RA has antinociceptive effects in neuropathic pain models. S1RA prevents mechanical and cold hypersensitivity in Oxaliplatin (HY-17371)-treated mice[1][2].
3-hydroxy-4-methyl-3'-(4-methyl-5-oxooxolan-2-yl)-octahydrospiro[oxolane-2,9'-pyrrolo[1,2-a]azepin]-5-one
5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-2-ol
(2s,3s,4r,5r)-2-[(2e,4e,6e)-deca-2,4,6-trien-2-yl]-4-methoxy-5-methyloxan-3-yl 2-aminoacetate
C19H31NO4 (337.22529660000004)
(1r,5r,7r,8r,12s,18r)-5,7,8-trimethyl-2,10,19-trioxa-15-azatetracyclo[10.5.1.1⁵,⁸.0¹⁵,¹⁸]nonadecane-3,9-dione
2,10-dimethyl-1-(2-methyl-1,3-thiazol-4-yl)trideca-1,5-diene-3,11-diol
(1s,4z,6r,7s,11r)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
(1r,3r,5s,6r)-8-methyl-6-[(3-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-4-hydroxy-3-methylbut-2-enoate
(1r,4s,6s,7s,17r)-4-ethyl-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
(1r,4e,6r,7r,11s,17r)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 5-ethyl-2,3-dimethyl-6-oxooxane-2-carboxylate
(1r,3s,5s,6r,7r)-7-hydroxy-8-methyl-3-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-6-yl (2z)-2-methylbut-2-enoate
5-(1h-indol-2-ylmethyl)-1,1,5,6-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-2-ol
(3S,3'R,4'R,9S,9aS)-4'-hydroxy-3'-methyl-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5'-oxolane]-2'-one
{"Ingredient_id": "HBIN009621","Ingredient_name": "(3S,3'R,4'R,9S,9aS)-4'-hydroxy-3'-methyl-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5'-oxolane]-2'-one","Alias": "(3S,3'R,4'R,9S,9aS)-4'-hydroxy-3'-methyl-3-[(2S,4S)-4-methyl-5-oxo-2-tetrahydrofuranyl]-2'-spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5'-tetrahydrofuran]one; (3S,3'R,4'R,9S,9aS)-4'-hydroxy-3'-methyl-3-[(2S,4S)-4-methyl-5-oxo-oxolan-2-yl]spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5'-oxolane]-2'-one; (3S,3'R,4'R,9S,9aS)-4'-hydroxy-3-[(2S,4S)-5-keto-4-methyl-tetrahydrofuran-2-yl]-3'-methyl-spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5'-tetrahydrofuran]-2'-one; (3S,3'R,4'R,9S,9aS)-4'-hydroxy-3'-methyl-3-[(2S,4S)-4-methyl-5-oxo-tetrahydrofuran-2-yl]spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5'-tetrahydrofuran]-2'-one","Ingredient_formula": "C18H27NO5","Ingredient_Smile": "NA","Ingredient_weight": "337.41","OB_score": "85.51848529","CAS_id": "885056-81-5","SymMap_id": "SMIT10570","TCMID_id": "NA","TCMSP_id": "MOL009441","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
7-hydroxy-3,6-bis(tigloyloxy)tropane
{"Ingredient_id": "HBIN013226","Ingredient_name": "7-hydroxy-3,6-bis(tigloyloxy)tropane","Alias": "NA","Ingredient_formula": "C18H27NO5","Ingredient_Smile": "CC=C(C)C(=O)OC1CC2C(C(C(C1)N2C)OC(=O)C(=CC)C)O","Ingredient_weight": "337.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9855","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "21159066","DrugBank_id": "NA"}
(1r,2s,4ar,5'r,8s,8ar)-5'-benzyl-2'-hydroxy-2,8-dimethyl-4a,5,6,7,8,8a-hexahydro-2h,5'h-spiro[naphthalene-1,3'-pyrrol]-4'-one
(2s,3r,4s,5s)-2-[(2e,4e,6e)-deca-2,4,6-trien-2-yl]-4-methoxy-5-methyloxan-3-yl 2-aminoacetate
C19H31NO4 (337.22529660000004)
(2s,3r,3's,4r,9'as)-3-hydroxy-4-methyl-3'-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-octahydrospiro[oxolane-2,9'-pyrrolo[1,2-a]azepin]-5-one
(1e,3s,5z,10s,11r)-2,10-dimethyl-1-(2-methyl-1,3-thiazol-4-yl)trideca-1,5-diene-3,11-diol
6'-hydroxy-4-methyl-3'-(4-methyl-5-oxooxolan-2-yl)-octahydrospiro[oxolane-2,9'-pyrrolo[1,2-a]azepin]-5-one
(2s,4as,5r,6r)-5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-2-ol
1-[(9s)-16-hydroxy-15-methoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaen-10-yl]butan-1-one
C21H23NO3 (337.16778480000005)
(1r,5r,7r,8s,12s,18r)-5,7,8-trimethyl-2,10,19-trioxa-15-azatetracyclo[10.5.1.1⁵,⁸.0¹⁵,¹⁸]nonadecane-3,9-dione
(1r,3r,5s,6s,7r)-7-hydroxy-8-methyl-3-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-6-yl (2e)-2-methylbut-2-enoate
4-[(8ar)-6-(4-hydroxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-7-yl]-2-methoxyphenol
C21H23NO3 (337.16778480000005)
(1r,4z,6r,7s,11s,17s)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
(2s,5r,6s,8ar)-5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-2-ol
[(1s,7r)-7-{[(2e)-2-methylbut-2-enoyl]oxy}-hexahydro-1h-pyrrolizin-1-yl]methyl (2z)-2-(hydroxymethyl)but-2-enoate
(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 5-ethyl-2,3-dimethyl-6-oxooxane-2-carboxylate
4-[6-(4-hydroxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-7-yl]-2-methoxyphenol
C21H23NO3 (337.16778480000005)
7-hydroxy-8-methyl-3-[(2-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-6-yl 2-methylbut-2-enoate
(4z,11s)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
8-methyl-6-[(3-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 4-hydroxy-3-methylbut-2-enoate
(1r,4e,7r,8r,12s,18r)-8-hydroxy-5,7,8-trimethyl-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-ene-3,9-dione
(2s,3's,4r,6'r,9'as)-6'-hydroxy-4-methyl-3'-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-octahydrospiro[oxolane-2,9'-pyrrolo[1,2-a]azepin]-5-one
{7-[(2-methylbut-2-enoyl)oxy]-hexahydro-1h-pyrrolizin-1-yl}methyl 2-(hydroxymethyl)but-2-enoate
(1r,4z,6r,7r,11s,17r)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
(1r,3r,5s,6r)-8-methyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-3-yl (2e)-4-hydroxy-3-methylbut-2-enoate
(1r,4z,6r,7s,11s,17r)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
1-[(2r)-2-hydroxypropyl]-2-methyl-6-(3-methylbut-2-en-1-yl)-9h-carbazole-3,4-dione
C21H23NO3 (337.16778480000005)
1-(2-hydroxypropyl)-2-methyl-6-(3-methylbut-2-en-1-yl)-9h-carbazole-3,4-dione
C21H23NO3 (337.16778480000005)
4-ethylidene-7-hydroxy-7-methyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,6,8-trione
8-hydroxy-5,7,8-trimethyl-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-ene-3,9-dione
(1r,4e,7r,11s,17r)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
5-[(4-hexyl-5-methylpyrrol-2-ylidene)methyl]-4-methoxy-1h,1'h-2,2'-bipyrrole
C21H27N3O (337.21540120000003)
5,7,8-trimethyl-2,10,19-trioxa-15-azatetracyclo[10.5.1.1⁵,⁸.0¹⁵,¹⁸]nonadecane-3,9-dione
(1r,4z,6s,7r,11s,17s)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
(2s,5r,6r,8ar)-5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-2-ol
(1r,3s,5s,6r,7r)-7-hydroxy-8-methyl-3-{[(2e)-2-methylbut-2-enoyl]oxy}-8-azabicyclo[3.2.1]octan-6-yl (2e)-2-methylbut-2-enoate
5-(1h-indol-3-ylmethyl)-1,1,5,6-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-2-ol
4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
1-{3-[1-(1h-indol-3-ylmethyl)piperidin-2-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone
C21H27N3O (337.21540120000003)
2-hydroxy-13-(1-hydroxypropyl)-1h,4h,5h,6h,7h,9h,10h,11h,13h,16h,16ah-pyrido[2,1-d]1,5,9-triazacyclotridecane-8-carbaldehyde
C18H31N3O3 (337.23652960000004)
(1r,4e,7s,8s,12s,18r)-8-hydroxy-5,7,8-trimethyl-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-ene-3,9-dione
(1r,4e,6s,7r,11r,17s)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
(2s,4as,5r,6r)-5-(1h-indol-2-ylmethyl)-1,1,5,6-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-2-ol
1-{3-[(2r)-1-(1h-indol-3-ylmethyl)piperidin-2-yl]-5,6-dihydro-4h-pyridin-1-yl}ethanone
C21H27N3O (337.21540120000003)
(1r,4s,6s,7s,11s,17r,18r)-4-hydroxy-6,7,18-trimethyl-2,9-dioxa-14-azatetracyclo[9.5.1.1⁴,⁷.0¹⁴,¹⁷]octadecane-3,8-dione
4-[(1e)-3-({4-[(3-aminopropyl)amino]butyl}amino)prop-1-en-1-yl]-2,6-dimethoxyphenol
C18H31N3O3 (337.23652960000004)
(1r,5s,7r,8r,12s,18r)-5,7,8-trimethyl-2,10,19-trioxa-15-azatetracyclo[10.5.1.1⁵,⁸.0¹⁵,¹⁸]nonadecane-3,9-dione
[(1s,7r,7ar)-7-{[(2e)-2-methylbut-2-enoyl]oxy}-hexahydro-1h-pyrrolizin-1-yl]methyl (2z)-2-(hydroxymethyl)but-2-enoate
(1s,4e,7r,8s,12r,18s)-8-hydroxy-5,7,8-trimethyl-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-ene-3,9-dione
(1r,5s,7r,8r,12r,18r)-5,7,8-trimethyl-2,10,19-trioxa-15-azatetracyclo[10.5.1.1⁵,⁸.0¹⁵,¹⁸]nonadecane-3,9-dione
(13s,16ar)-2-hydroxy-13-[(1s)-1-hydroxypropyl]-1h,4h,5h,6h,7h,9h,10h,11h,13h,16h,16ah-pyrido[2,1-d]1,5,9-triazacyclotridecane-8-carbaldehyde
C18H31N3O3 (337.23652960000004)
3-[(2z)-4-{4-[(acetyloxy)methyl]-4-hydroxycyclohexyl}-5-oxofuran-2-ylidene]-2-methylpropanimidic acid
2-[(2s,6r)-6-[(2r)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone
(1r,5s,7r,8s,12s,18r)-5,7,8-trimethyl-2,10,19-trioxa-15-azatetracyclo[10.5.1.1⁵,⁸.0¹⁵,¹⁸]nonadecane-3,9-dione
(1r,4z,7s,8s,12s,18r)-8-hydroxy-5,7,8-trimethyl-2,10-dioxa-15-azatricyclo[10.5.1.0¹⁵,¹⁸]octadec-4-ene-3,9-dione
4-ethyl-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
6-hydroxy-4-isopropyl-5,6-dimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
8-methyl-6-[(2-methylbut-2-enoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 4-hydroxy-3-methylbut-2-enoate
(1r,4z,6r,7r,11r,17r)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,8-dione
3-(4-{4-[(acetyloxy)methyl]-4-hydroxycyclohexyl}-5-oxofuran-2-ylidene)-2-methylpropanimidic acid
9-(4-aminophenyl)-3,7-dihydroxy-2,4,6-trimethyl-9-oxononanoic acid
5-{[(2z)-4-hexyl-5-methylpyrrol-2-ylidene]methyl}-4-methoxy-1h,1'h-2,2'-bipyrrole
C21H27N3O (337.21540120000003)